NCT01559818View on ClinicalTrials.gov

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

IMM-101

IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.

Trial Locations (1)

Unknown

St Georges University of London, London

Sponsors
All Listed Sponsors
lead

Immodulon Therapeutics Ltd

INDUSTRY

NCT01559818 - A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | Biotech Hunter | Biotech Hunter